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Background and Purpose: Functional brain imaging using genetically encoded Ca2+
sensors in larval zebrafish is being developed for studying seizures and epilepsy as a
more ethical alternative to rodent models. Despite this, few data have been gener-
ated on pharmacological mechanisms of action other than GABAA antagonism.
Assessing larval responsiveness across multiple mechanisms is vital to test the trans-
lational power of this approach, as well as assessing its validity for detecting
unwanted drug-induced seizures and testing antiepileptic drug efficacy.
Experimental Approach: Using light-sheet imaging, we systematically analysed the
responsiveness of 4 days post fertilisation (dpf; which are not considered protected
under European animal experiment legislation) transgenic larval zebrafish to treat-
ment with 57 compounds spanning more than 12 drug classes with a link to seizure
generation in mammals, alongside eight compounds with no such link.
Key Results: We show 4dpf zebrafish are responsive to a wide range of mechanisms
implicated in seizure generation, with cerebellar circuitry activated regardless of the
initiating pharmacology. Analysis of functional connectivity revealed compounds
targeting cholinergic and monoaminergic reuptake, in particular, showed phenotypic
Abbreviations: 4-AP, 4-aminopyridine; AChE, acetylcholinesterase; Cis-ACPD, ((±)-1-aminocyclopentane-cis-1,3-dicarboxylic acid); DAT, dopamine transporter; dpf, days post fertilisation; Kv,
voltage-gated K+ channel; NET, noradrenaline transporter; PDE, phosphodiesterase; PF-06767832, (1,5-anhydro-2,3-dideoxy-3-[[[5-methyl-4-[[4-(4-thiazolyl)phenyl]methyl]-2-pyridinyl]
carbonyl]amino]-L-threo-pentitol, N-((3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl)-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]-pyridine-2-carboxamide); PTZ, pentylenetetrazole; SB205607 or TAN-
67, ((R*,S*)-(±)-2-methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide); SERT, 5-HT/serotonin transporter; SNC80, ((+)-4-[(αR)-α-((2S,5R)-
4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide); TEA, tetraethylammonium chloride; XE991, (10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone dihydrochloride).
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consistency broadly mapping onto what is known about neurotransmitter-specific cir-
cuitry in the larval zebrafish brain. Many seizure-associated compounds also exhibited
altered whole brain functional connectivity compared with controls.
Conclusions and Implications: This work represents a significant step forward in
understanding the translational power of 4dpf larval zebrafish for use in neurophar-
macological studies and for studying the events driving transition from small-scale
pharmacological activation of local circuits, to the large network-wide abnormal syn-
chronous activity associated with seizures.
K E YWORD S
3Rs, CNS safety pharmacology, drug discovery/target validation, functional neuroimaging,
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1 | INTRODUCTION
Functional brain imaging using genetically encoded Ca2+ sensors in
optically transparent larval zebrafish offers an extremely powerful
approach for analysing the in vivo response of the vertebrate brain
to drug treatment. Despite its undoubted power, this approach has
yet to be widely used in neuropharmacological studies. A research
area that is beginning to exploit this methodology is the study of
seizures and the chronic seizurogenic condition, epilepsy (Burrows
et al., 2020). Traditionally, seizures have been classified as the culmi-
nation of abnormal neuronal excitation that progresses to hyper-
synchronous excitation across large-scale neural circuits. Most
animal models of seizures and epilepsy rely upon unbalancing excit-
atory and inhibitory synaptic influences using pharmacological
(or electrical) stimulation (Staley, 2015). Whilst this process is often
exploited for anti-epileptic drug development (Kandratavicius
et al., 2014), this can also occur through the inadvertent action of
chemicals, including drugs (Ruffmann et al., 2006). The exact mecha-
nisms that lead to seizures are not fully understood (Scharfman, 2007)
and a major challenge is that, to understand the mechanistic basis of
seizure generation and identify novel drug targets, studies of brain
networks linking local and global scales are crucial (Rossi et al., 2018;
Staley, 2015). Importantly, and in contrast with other current animal
models, functional brain imaging in the larval zebrafish allows this and
also provides a more direct indicator of neural activity than, for exam-
ple, behavioural assessments of convulsions (Winter et al., 2008).
Consequently, a number of recent studies have focussed on func-
tional imaging in the zebrafish larval brain after exposure to the model
seizure-precipitant and GABAA antagonist pentylenetetrazole (PTZ),
as well as a small number of other seizurogenic tool compounds
(Diaz Verdugo et al., 2019; Liu & Baraban, 2019; Rosch et al., 2018;
Turrini et al., 2017; Winter et al., 2017) or have demonstrated the
application of this methodology in assessing the efficacy of anti-
epileptic drugs in genetic or PTZ-induced epilepsy models (Ghannad-
Rezaie et al., 2019; Lin et al., 2018). The fact that functional brain
imaging studies using larval zebrafish have focussed on one or two
mechanisms of initiation, however, means that we still do not have a
clear idea of whether neural network hyperexcitation induced by
other drug types can be detected using this approach and what those
neural imaging signatures look like (Burrows et al., 2020). Such infor-
mation is critical both for assessing the validity of this approach for
the detection of unwanted neuroactivity during drug development
and its application for the discovery of new antiepileptic drugs.
Furthermore, understanding the neuropharmacological responsive-
ness of the larval zebrafish provides important validation data on the
applicability of this model for more fundamental mechanistic studies
of seizures and epilepsy, and on the translational power of the larval
What is already known
• Functional brain imaging in larval zebrafish offers a pow-
erful approach for profiling neuroactive drugs.
• Translational power of this approach across multiple drug
types has yet to be fully tested.
What this study adds
• We show that the larval zebrafish brain is responsive to a
range of seizurogenic drugs.
• Distinct phenotypes are associated with seizurogenic
compound exposure and with certain initiating mecha-
nisms of action.
What is the clinical significance
• This approach appears appropriate for neuropharmaco-
logical profiling and for detecting the seizurogenic poten-
tial of drugs.
• This approach also has potential as an alternative in vivo
model for studying epileptogenic mechanisms.
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zebrafish for use in imaging-focussed neuroscience studies more
widely.
To address this knowledge gap, using four-dimensional functional
brain imaging, we systematically tested the responsiveness of 4 days
post fertilisation (dpf) larval zebrafish to 57 compounds with a known
link to seizure generation in mammals and spanning more than 12 drug
classes, alongside eight compounds with no such link. We opted to
use 4dpf zebrafish as these are not considered protected vertebrates
under European animal legislation and therefore ethically preferable,
particularly for use in higher throughput screens where animal usage
can be high. In addition, the use of 4dpf larvae allows unfettered func-
tional imaging in the vertebrate brain in the absence of the con-
founding effects of a general anaesthetic. With this experimental
approach, we sought to address these key questions:- (1) Are 4dpf lar-
val zebrafish responsive to a range of molecular mechanisms linked to
network hyperexcitation in mammals? (2) Are there phenotypic fea-
tures that allow for differentiation between nonseizurogenic and pro-
seizurogenic compounds and/or particular pharmacologies? (3) Are
there brain regions that appear particularly important for the initiation
and/or propagation of seizure-like network activity regardless of the
initiating mechanism? (4) Are the resultant spatiotemporal patterns of
neural activity consistent with our knowledge of neurotransmitter-
specific brain circuitry in the larval zebrafish?
2 | METHODS
The experimental approach is detailed in the following sections and
the process is summarised in Figure 1. Throughout, the data shown in
graphs and tables are the means ± SEM of data points from individual
animals (n). Statistical analysis was undertaken using larvae as the
individual replicate values and only where the sample size was at least
n = 5. Due to data loss, one dataset contained an n = 4 (picrotoxin at
the lowest treatment level of 15 μM) and in this case, this treatment
was not subject to statistical assessment. ‘Outliers’ were not excluded
from the analyses or presentation of data. This manuscript complies
with British Journal of Pharmacology recommendations and require-
ments on experimental design and analysis (Curtis et al., 2018).
2.1 | Experimental animals
4dpf transgenic zebrafish with a pan-neuronal Ca2+ sensor (elavl3:
GCaMP6s) were used for the imaging. Adult elavl3:GCaMP6s
broodstock (Vladimirov et al., 2014), originally obtained from Dr.
Misha Ahrens (Janelia Research Campus, Howard Hughes Medical
Institute, Ashburn, Virginia, USA), were held in aquaria at the Univer-
sity of Exeter, at 28 ± 1C under optimal conditions for spawning
(12-h light: 12-h dark cycle, with 20-min dusk–dawn transition
periods). Culture water consisted of mains tap water which was fil-
tered by reverse osmosis (Environmental Water Systems UK Ltd.) and
then reconstituted with Analar-grade mineral salts to a standard syn-
thetic freshwater composition (final ion concentrations: 117 mgL−1
CaCl2.2H20, 25.0 mgL−1 NaHCO3, 50 mgL−1 MgSO4.7H20,
2.3 mgL−1 KCl, 1.25 mgL−1 Tropic Marine Sea Salt, giving a conduc-
tivity of 300 mS). The culture water was aerated and heated to 28
± 1C before being supplied to individual zebrafish tanks on a semi-
re-circulatory system. Water was routinely monitored for tempera-
ture, pH, conductivity, ammonia, nitrite and nitrate, all of which were
maintained within appropriate limits for zebrafish. Spawning occurred
at the time of lights on and was encouraged by provision of a
spawning substrate. Fertilized eggs were collected shortly after
spawning, bleached for 1 min in 1% w/v chloramine T (Sigma-Aldrich,
Poole, UK) in culture water, rinsed with fresh culture water and
transferred to Petri dishes which were filled with culture water and
held at 28 ± 1C, under the same lighting conditions until use in
experiments at 4dpf. All work was undertaken under project and
personnel licences granted by the UK Home Office under the UK
Animals (Scientific Procedures) Act and approved by the University of
Exeter's Animal Welfare and Ethical Review Body and with the recom-
mendations made by the British Journal of Pharmacology (Lilley
et al., 2020).
2.2 | Test compounds
The range of drug types assessed spanned agents targeting multiple
mechanisms implicated in the initiation of neural network
hyperexcitation (Easter et al., 2009) and comprised many compounds
which have not, to our knowledge, been tested before in zebrafish.
The compounds tested encompassed those implicated in the induc-
tion of seizures in humans or nonclinical models via a range of molec-
ular mechanisms and those with no known association with seizures
(Figure 2). Compounds were selected following an extensive review of
available published data. This review allowed us both to identify com-
pounds with a link to seizures in preclinical or clinical studies and to
select appropriate pharmacological probes known to act via mecha-
nisms implicated in the generation of neural network hyperexcitation.
The compiled list was not considered exhaustive but rather designed
to encompass several examples acting through related mechanisms of
action. Based on the strength of the supporting literature, we cat-
egorised the selected compounds as follows: category A tool com-
pounds typically used in animal models of seizures or epilepsy;
category B compounds for which there is strong evidence for an asso-
ciation with seizures from clinical or nonclinical animal data; category
C compounds for which there is some evidence supporting a link with
(non) clinical seizures; category D compounds for which there are lim-
ited reports of an association or where seizures are induced only
under specific exposure scenarios such as during overdose (e.g
morphine) or withdrawal (e.g. ethanol); category E compounds for
which there is a clear mechanistic link but for which literature data on
seizure induction are absent (typically pharmacological probes) and
category F compounds for which no evidence or mechanistic associa-
tion with seizure induction was evident (negative controls). The final
classification was agreed a priori by all study participants based upon
the information available following the reviewed literature.
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F IGURE 1 Schematic of the experimental process used to obtain 4D whole brain neural activity data from drug treated larval elavl3:
GCaMP6s zebrafish. The experimental process and resultant data analysis procedures are summarised in order of panels a–d. (a) Animals were
first exposed to the compound and then imaged using light sheet microscopy. (b) The resultant image stacks were 3D aligned to a standardised
brain image library (Z-brain atlas) and subsequent 3D registration allowed extraction of anatomical region-specific fluorescence data. (c) The
extracted region-specific fluorescence intensity temporal profiles were then analysed to reveal regional changes between treated and untreated
animals. (i) Peaks were automatically identified from the temporal profiles (e.g. labelled 1–6) and (ii) peak parameters for each profile extracted.
(iii) Peak height and area under the curve (AUC) were then analysed using univariate statistics to identify brain regions showing altered neural
activity versus the same area in the corresponding group of control animals. (d) For the analysis of functional connectivity (FC), (i) Pearson's
correlation coefficients (r) were calculated between the temporal activity profiles of each pair of regions to provide a matrix summarising
measures of the level of functional connectivity between each pair of nodes. An r value of >0.7 between two regions suggested these areas were
functionally connected as both showed correlated temporal activity profiles. (ii) Multivariate statistical analysis of the FC data was then
undertaken, followed by cluster analysis of the resultant Euclidean distances, to assess similarities in the resultant phenotypes and whether
groupings contained compounds sharing common mechanisms of pharmacological action. Post hoc testing of the resultant groupings using
Kruskal–Wallis tests then revealed the brain regions and/or connections driving these similarities/differences. (iii) The r values from the FC
matrices generated for each compound were visualised in the form of a connectivity map of the brain (a functional connectome  upper panel)
and as exposed animal data versus the resting state network by comparing the r values for each connection between treated and untreated
groups using Mann–Whitney U tests (lower panel)
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F IGURE 2 Summary of the test chemicals and experimental exposure conditions used in the current study. Information shown left to
right: compound name; strength of the association with seizure induction in mammals (see below); Chemical Abstracts Service (CAS)
registry number; abbreviation as used in other figures; pharmacological class; primary mechanism of action; and exposure concentration and
times used the Ca2+ imaging. The strength of the association with seizure induction in mammals based on the scientific literature is
classified as follows: A - strong link—tool compounds/precipitants; B - clear association in clinic/nonclinical studies; C - measurable
association in clinic and/or some nonclinical evidence; D - limited clinical/non clinical data, but weak or conflicting and/or seizure-inducing
only under specific circumstances (e.g., overdose or withdrawal); E - mechanistic link only, no published confirmatory data; and F - no
known link to seizures (seizure negative). Abbreviations: AChE = acetylcholine esterase; DR = dopamine receptor; αR = α-adrenoreceptor;
HR = histamine receptor; mAChR = muscarinic acetylcholine receptor; 5-HTR = 5-hyroxytryptamine receptor; GABAR = γ-aminobutyric acid
receptor; KAR = kainic acid receptor; NMDAR = glutamatergic N-methyl-D-aspartate receptor; GLYR = glycine receptor; Kv = voltage-gated
K+ channel; NA = noradrenaline; DA = dopamine; 5-HT = 5-hyroxytryptamine (serotonin); P1 = adenosine receptor; PDE = phosphodiesterase;
μ/δ-opioidR = mu/delta-opioid receptor; LOQ = limit of quantification. *DMCM (methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate);
**cis-ACPD ((±)-1-Aminocyclopentane-cis-1,3-dicarboxylic acid); ***XE991 (10,10-bis(4-Pyridinylmethyl) -9(10H)-anthracenone
dihydrochloride); ****PF-06767832 (1,5-Anhydro-2,3-dideoxy-3-[[[5-methyl-4-[[4-(4-thiazolyl)phenyl]methyl]-2-pyridinyl]carbonyl]amino]-L-
threo-pentitol, N-((3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl)-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]-pyridine-2-carboxamide); *****SNC80
((+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide); ******SB205607 or TAN-67, ((R*,S*)-
(±)-2-methyl-4aa-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aa-octahydroquinolino[2,3,3-g]isoquinoline dihydrobromide); *******BW373U86 4-[(αR*)-
α-((2S*,5R*)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl]-N,N-diethylbenzamide). All test chemicals were obtained from sigma-Aldrich
(Gillingham, UK) or Tocris (Bristol, UK)
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2.3 | Selection of exposure concentration ranges
and durations
The concentration ranges and exposure durations used in the func-
tional imaging in 4dpf larvae were selected using information gained
from a separate assessment of compound effects on locomotion in
7dpf larval, using a previously described standardised assay (see
Winter et al., 2008). Bioanalysis of internal (whole body) compound
concentrations were carried out in the same 7dpf animals using liquid
chromatography with tandem mass. The results of this work on 7dpf
larvae are summarised in Figure S1 and the methods used briefly out-
lined in the Supporting Information. The internal compound concen-
trations in 7dpf larvae only provide an estimate of actual internal
compound concentrations in the 4dpf larvae, but collectively, these
data helped both to select the initial exposure conditions used for the
4dpf functional imaging assessment (e.g., high uptake supported a
short exposure period and lower concentration range and vice versa),
and to interpret the resultant functional imaging data (e.g., where the
absence of a biological effect might be explained by poor compound
uptake).
2.4 | Drug treatment and light sheet microscopic
imaging
We aimed to generate equally sized datasets of n = 8 animals per
treatment in our exposures for which the imaging logistics required
the treatments to be run over two separate days on two batches of
embryos (i.e. from two separate spawnings). Each treatment was
equally represented over the 2 days of experimentation and the
experimental process undertaken identically. Although treatments
were not blinded, each larva was randomly selected and assigned to
test compound at one of three concentrations or to a fish culture sys-
tem water (vehicle) control for the exposure durations detailed in
Figure 2. Following exposure, each animal was imaged as described
below. The order in which animals were exposed and imaged was
rotated through all treatments on each day to remove any bias associ-
ated with the time of day used for assessment. The need to hold
larvae motionless during imaging to avoid movement artefacts, whilst
avoiding introducing the widespread confounding effects of using a
general anaesthetic, necessitated the use of a neuromuscular blocker.
Tubocurarine was selected as a non-depolarizing neuromuscular
blocker (nicotinic acetylcholine antagonist) with a stable and long
duration of action (Appiah-Ankam & Hunter, 2004) and was applied at
a concentration of 4 mM to induce rapid paralysis appropriate for the
acute exposure regimen of our study. Although tubocurarine has been
associated with histamine release and resultant hypotension clinically,
importantly it exhibits no muscarinic receptor (mAChR) antagonist
activity and is water soluble. Furthermore, it has been used to paral-
yse zebrafish in previous functional imaging studies (Favre-Bulle
et al., 2018; Miyazawa et al., 2018; Tao et al., 2011; Vanwalleghem
et al., 2020). Adding to this, we observed no evidence of the attenu-
ated neuromuscular blockade during acetylcholinesterase (AChE)
inhibitor application over the time scale we use for imaging after neu-
romuscular blocker application. Each larva was transferred to an
aqueous mixture of compound and tubocurarine (4 mM) until muscle
tone was lost (typically 1 min), then moved to tubocurarine and test
compound in 1.4% low melting point agarose and finally drawn into a
clear borosilicate glass capillary plugged with 2% low melting point
agarose. No organic solvents were employed to minimise potential
confounding effects and vehicle (water) control larvae were treated
identically (including the presence of neuromuscular blocker) but with-
out test compound. Larvae were positioned on the light sheet micro-
scope (Figure 1a) and dorsal-ventral optical sectioning undertaken in
the horizontal plane (10 equidistant Z-slices across 220 μm taken in
1.875 s, repeated 200 times). Following imaging, larval health was
confirmed through observation of a normal heart rate and blood flow.
In any functional imaging study there is trade-off between spatial
coverage and temporal resolution. Our imaging conditions were
optimised to obtain the fastest cycle time whilst maintaining whole
brain volume coverage at an appropriate temporal resolution. Some
previous studies have chosen to obtain higher temporal resolutions
across single focal plains, however in order to fully capture the spatial
component of neural network hyperexcitation and answer specific
questions about regional importance in seizure generation, we opted
for whole brain volume imaging at a mesoscale spatial resolution. The
importance of this scale of interrogation in the study of seizures has
recently been highlighted by Wykes et al. (2019) who pointed out that
seizure foci do not ‘operate in isolation’, exhibiting connectivity with
‘short and long range projections’ and that mesoscale study is
required in order to ‘record propagation pathways’, areas of the brain
that are recruited during seizure development and to detect abnor-
malities between ‘functionally connected but distant areas of the
brain’. Similarly, Rosch et al. (2018) acknowledged that epileptic sei-
zures are an ‘emergent property’ at the level of neuronal populations
and mesoscale modelling may provide insights that assessments at the
microscale do not. Accordingly, we used anatomically anchored image
registration to provide mesoscale segmentation of the whole brain in
3D and which provided the ability to compare equivalent regions
across different larvae and treatments using anatomical location as
the reference point for comparison. Further to this, in initial studies
we undertook in support of this work we identified that a 6-min
assessment period was sufficient to capture seizure-like activity after
drug treatment, whilst providing datasets of a manageable size
(Winter et al., 2017).
2.5 | Light sheet microscopic imaging settings
The light sheet microscope was custom built using the Open Access
platform for SPIM (Huisken, 2012; Pitrone et al., 2013) as previously
detailed in Winter et al. (2017). The system comprised a 488 nm
Argon laser (Melles Griot, Didam, Netherlands) for illumination, a
20×/0.5 NA objective lens (Olympus, Southend-on-Sea, UK) with an
intermediary magnification of 1×, followed by a 525/50 nm emission
filter and 495 nm bandpass filter (Chroma, Olching, Germany) to
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collect emitted light and a 5.5-MP Zyla sCMOS camera (30 frames per
second, 640 × 540 pixels, 4 × 4 binning, 40-ms exposure, Andor,
Belfast, Northern Ireland) to capture images. The camera and rota-
tional axis (Picard Instruments, Albion, USA) were controlled though
μManager and the OpenSPIM plugin (Pitrone et al., 2013). The Point
Spread Function of our system was determined by performing
Z-stacks of 50 × 0.5 μm fluorescent beads, embedded in 1% low melt-
ing point agarose within a glass capillary. Images were acquired at
z-intervals of 1.5 μm using the same system settings employed during
data acquisition (detailed above) and the PSF calculated using the
MOSAICsuite point spread function tool (http://imagej.net/
MOSAICsuite). The spatial resolution of our system was measured
using a segment from a multi-grid stage micrometer (Edmund Optics,
UK) with 100-μm divisions. The grid was imaged in the sample cham-
ber using the same optics and medium to determine the pixel length
of each 100-μm division. Each 100-μm division at 1 × 1 binning was
304 pixels and at 4 × 4 binning was 76 pixels.
2.6 | Image processing and peak parameter
measurements
Data extraction from resultant images was undertaken automatically
using a custom Python image processing pipeline developed at
the University of Exeter and as previously detailed in Winter et al.
(2017) (available at: https://gitlab.com/exeter-zebrafish-research/
zebrafish-neuroanalyser3d) (Figure 1b). Briefly, each image was ini-
tially down-sampled (3x3x1) and then 3D-aligned against a labelled
reference brain (Randlett et al., 2015) using registration against
14 user-selected key-points from a representative 3D image stack.
This brain atlas was established for use in 5-7dpf larvae, so we
undertook a full 3D affine transformation (optimised using the
Umeyama algorithm) that enabled alignment of our image series' to
the reference brain and allowed extraction of voxel intensity data
from defined anatomical regions of interest selected to encompass
only major (larger) brain structures. This brain atlas has been widely
used for anatomical registration including for a number of previous
functional imaging studies (e.g. Migault et al., 2018; Rosch
et al., 2018; Vanwalleghem et al., 2020). During processing, images
were automatically shift-corrected to account for any sample drift.
For this, the shape index function as defined by Koenderink and
van Doom (1992) was used to simultaneously correct for x, y and z-
drift using functions from the Scikit-image library (van der Walt
et al., 2014). Next, quantitative data were extracted for each region
of interest as the mean of incorporated voxels for each time
point, to generate a temporal profile of activity for that region.
These profiles were baseline subtracted using a sliding minimum fil-
ter comprising 50 time-points or the signal length if less than
50 time-points and peaks in activity were subsequently identified
and analysed (Figure 1c (i)). Fluorescence-intensity profiles then
underwent fine-scale smoothing using Gaussian filtering (σ = 1.5) to
remove high-frequency noise and activity peaks spanning 2 or more
consecutive imaging cycles were identified by subtracting the
baseline and applying a threshold of 2σ. From the identified activity
peaks in the profiles for each region of interest, time-averaged peak
height and Area Under the Curve (AUC—calculated as the sum of
the intensity values within each defined peak region) were calcu-
lated for each animal (referred to as ‘peak parameters’) as these
two metrics were found to be the most useful for defining activity
phenotypes (Figure 1c (ii)). We have previously described the per-
formance characteristics of our imaging process (Winter
et al., 2017). Briefly, the error of the 3D affine registration pro-
cesses was calculated as 27.56 ± 0.43 μm, the theoretical point
spread function was 0.751 μm, the measured lateral resolution was
0.76 pixels per micrometre and the temporal resolution was 1.875 s
per full brain volume.
2.7 | Data analysis—Describing the resting state
network
To describe the resting state network of 4dpf larvae analysed using
this methodology, analysis of the peak parameters across all vehicle
(water) control groups was undertaken. This analysis allowed us to
describe the relative levels of neural activity in different brain
regions under ‘resting’ conditions to establish which regions were
comparatively (in)active during imaging. When comparing between
regions of interests under such circumstances, it is important to
control for potential regional variations in elavl3:GCaMP6s expres-
sion and, therefore, data were first normalised by subtracting each
voxel's baseline, estimated using a sliding minimum filter (comprising
50 time-points or the signal length if less than 50 time-points)
and then dividing by this baseline value. Functional connectivity in
vehicle control larval brains was also assessed using the method
detailed below.
2.8 | Data analysis—Analysis of region-specific
GCamp6s fluorescence across the whole larval brain
To identify the neural network activity profile induced by each com-
pound and therefore measure the responsiveness of larvae across a
range of pharmacological mechanisms of action, univariate analysis of
the concentration–response relationships within each regions of inter-
est was undertaken (Figure 1c (iii)). For this, Kruskal–Wallis coupled
with Dunn's multiple comparisons tests (where an overall difference
was detected) were undertaken on the mean fluorescence peak height
or AUC value averaged across animals at each concentration, versus
the mean of the corresponding water control group (Bonferroni indi-
vidual α = .017). Baseline correction, as used to compare between
control animal regions of interests, was not undertaken for within-
regions of interest comparison of untreated and treated animal neural
activity to ensure due consideration of compound-induced changes in
‘baseline’ fluorescence. Furthermore, all treatment-related compari-
sons undertaken were between corresponding regions of interests
and consequently, no comparison of fluorescence was undertaken
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between regions of interests in treated animals, thus avoiding poten-
tial bias associated with regional differences in GCaMP expression in
these cases.
2.9 | Data analysis—Multivariate exploration of
larval brain functional connectivity
Functional connectivity in the context of neuroimaging pertains to the
relationship between the neuronal activity patterns of anatomically
separated brain regions, which in turn reflects the level of communica-
tion between these regions (van den Heuvel & Hulshoff Pol, 2010).
Practically, these relationships can be represented by measures of cor-
relation that reveal information on mesoscale or macroscale networks
responding to stimulation, in this case mediated by the action of
seizurogenic compounds. Here, multivariate analysis of functional
connectivity phenotypes was hypothesised to reveal information
about the activation or suppression of specific neural circuits follow-
ing compound treatment, by reflecting the spatial distribution of tar-
gets across the brain.
First, a connectivity matrix was generated for each animal by calcu-
lating the Pearson's correlation coefficient (r) between the time series'
of all possible pairs of regions of interests (Figure 1d (i)). Initial assess-
ment of concentration response curves showed that in the majority of
cases the maximal response of larvae (versus control data) to compound
treatment was apparent at the highest or second highest treatment
concentrations. Consequently, it was decided to use these two treat-
ment levels in the exploratory multivariate analysis. The lowest treat-
ment concentration data were not included as in most cases activity
levels were indistinguishable from controls and as such would likely
reduce the ability to distinguish the phenotypic effect of drug treatment.
The data for DMCM, domoic acid, Cis-ACPD, TEA, bethanechol,
theobromine and paraxanthine were also excluded from these analyses
as we found no evidence of compound uptake (see Section 3).
Multivariate analysis required a consistent number of regions of
interests across all experiments and therefore, regions of interests
that were inconsistently registered (i.e. were absent in >2% of larvae
analysed) during image processing as they occurred at the limits of
Z-plane penetration were excluded prior to analysis, leaving
39 analysed regions of interests per animal. All values from each con-
nectivity matrix were then reshaped into a connectivity vector (gener-
ating 741 regions of interest connections per larva) and the mean of
the vectors for all animals calculated to provide one vector per com-
pound (Figure 1d (ii)). To allow visualisation of similarities or differ-
ences between resultant profiles and to generate groups on which
post hoc statistical analysis could be undertaken, a simple
unsupervised agglomerative hierarchical cluster analysis (‘unweighted
pair group method with arithmetic mean’ or UPGMA) was under-
taken. This was considered the best approach where no prior informa-
tion on the relative importance of any particular data feature was
known. For this, the Euclidean distances between vectors of all of the
compounds were calculated to provide a value for similarity between
each compound within the multivariate feature space,and UPGMA
cluster analysis undertaken. The same analysis was also undertaken
on all control animal data to provide confidence that the observed
clustering of ‘related' compounds was not driven by potential differ-
ences in the baseline levels of GCaMP fluorescence between experi-
mental runs (Figure S2).
2.10 | Data analysis—Post hoc assessment of
phenotype-defining data features
Next, to assess whether the groupings identified by cluster analysis
were based upon phenotypic similarities amongst grouped com-
pounds and to test the hypothesis that certain data features differ
between primary pharmacological mechanisms of action, post hoc
statistical comparisons between compound-treated larvae and the
resting state network were undertaken (Figure 1d (ii)). For this,
Mann–Whitney U tests with a highly conservative Bonferroni correc-
tion (α = .000055) (due to the high number of comparison undertaken
on each matrix) were used to identify statistically significant differ-
ences between compound-treated and control functional connectivity
phenotypes, by comparing the r values obtained for all pairs of regions
of interests. A difference between these two values would suggest an
increase or decrease in the strength of that connection between the
two groups, and help to determine whether any brain regions or func-
tional connections were particularly prevalent within a specific group-
ing, and provide more confidence in the significance of groupings
identified from the cluster analyses.
2.11 | Data analysis—Overall functional
connectivity as an indicator of altered network
synchronicity
Traditionally, a key defining feature of seizures is the occurrence of
hypersynchronicity between disparate brain regions. It has, however,
been acknowledged that the interictal–ictal cycle is likely to incorpo-
rate aspects of both hypersynchronicity and hyposynchronicity
depending on the point in the cycle at which assessment is made and
the spatiotemporal resolution of the detection methods used (Jiruska
et al., 2013). With this in mind and given there is currently no univer-
sally accepted classification of epileptiform brain activity within Ca2+
imaging datasets (Burrows et al., 2020), here we compared
compound-treated and resting state network average functional con-
nectivity (both average r values and numbers of connections with an
r value >0.7) using Mann–Whitney U tests (p < .05) (Figure 1d (iii)).
These data were taken as an indicator of the degree to which syn-
chronisation between regions was occurring compared with that
observed in the resting state network. It was hypothesised that an
increase in the number of functional connections and/or the strength
of those connections may allow differentiation between
nonseizurogenic and pro-seizurogenic compounds acting via a range
of primary initiating mechanisms. Analysis of average functional con-
nectivity was undertaken across all brain regions combined and also
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separately on the average of those connections that involve only
regions within the telencephalon, diencephalon, mesencephalon, or
the rhombencephalon, in order to assess changes in macroscale func-
tional connectivity.
2.12 | Materials
All test chemicals are detailed in full, along with their Chemical
Abstracts Services (CAS) registry numbers, in Figure 2 and its
accompnaying legend. All test chemcials and reagents were obtained
from Sigma-Aldrich (Gillingham, UK) or Tocris (Bristol, UK).
2.13 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOL-
OGY http://www.guidetopharmacology.org and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander, Christopoulos, et al., 2019; Alexander, Fabbro,
et al., 2019; Alexander, Kelly, et al., 2019; Alexander, Mathie,
et al., 2019).
3 | RESULTS
3.1 | The resting state network involves activation
of hindbrain autonomic, sensory and motor centres
Analysis across all vehicle (water) control larvae was undertaken to
describe the resting state network of animals analysed using our
experimental setup. Analysis of the peak parameter data revealed
low-magnitude, high-frequency neural activity, most frequently in
hindbrain regions functionally associated with homeostatic control,
sensory processing, arousal and motor activity (Figure 3a). Analysis of
functional connectivity (Figure 3b) further supported this with the
strongest functional connections and most connected regions also
predominantly associated with these physiological processes.
3.2 | The 4dpf larval zebrafish is responsive to a
range of molecular mechanisms known to induce
neural network hyperexcitation in mammals
Peak parameter analysis revealed that many compound-treated larvae
exhibited increases (net regional activation) or in some cases
decreases (net regional inhibition) in GCaMP6s fluorescence in
specific anatomical regions, when compared with the corresponding
vehicle (water) controls (Figure 4). In the majority of cases,
concentration–response relationships were also evident supporting
compound-induced modification of neural activity (Figure S3).
Exposure to GABAA receptor, glycine receptor, AChE and NA/5-HT/
DA modulating compounds generally resulted in a higher number
of changes in activity within specific brain regions when compared
with other pharmacological classes. Also of note, neural activity
in hindbrain regions and in particular the cerebellum and its sub
regions, the corpus cerebelli and valvula cerebelli, were more fre-
quently altered after exposure to compounds associated with sei-
zure induction (Figure S4). In contrast, a number of potentially
seizurogenic compounds showed no alteration of fluorescence
intensity versus the water controls in any brain region. Of these
DMCM, domoic acid, Cis-ACPD, TEA, bethanechol, theobromine
and paraxanthine showed no observable effects in the separate
maximum tolerated concentration or locomotor assessment of
7dpf animals and no differences in GCaMP6s fluorescence peak
height or AUC. There was also no evidence of uptake for these
compounds (<2% of the external concentration or not measurable)
in 7dpf animals suggesting a lack of internal exposure might explain
the inactivity observed in 4dpf larvae here (compound name
highlighted in light grey in Figure S1). Low internal exposure, how-
ever, was less likely to explain an absence of altered peak height or
AUC after exposure to 4-AP, PF-06767832, SNC80, meperidine,
physostigmine, maprotiline, cocaine and theophylline. Exposure to
clonidine and quinine, two compounds not normally associated with
CNS excitation in mammals, conversely resulted in significantly ele-
vated GCaMP-fluorescence in certain brain regions, especially in the
case of clonidine
When the number of brain regions exhibiting an increase or
decrease in peak height or AUC were assessed (AUC data in
Figure S5), strongly seizurogenic compounds generally showed more
regions with elevated activity and fewer with reduced activity com-
pared with the nonseizurogenic compounds. Notable exceptions were
clonidine and quinine, as mentioned, and the ‘positive’ compounds
fentanyl, carbachol and amitriptyline, which showed reductions in
activity across multiple brain regions. Weaker seizurogenics and those
categorised as showing seizure liability only under specific circum-
stances (category D in Figure 2) tended to locate away from the two
extremes showing fewer significant changes in brain activity per se.
3.3 | Similarities in functional connectivity
phenotypes of larvae exposed to monoaminergics and
cholinergics
The functional connectomes resulting from exposure to each
compound are shown in Figure S6 with an overview of published
data on target distribution summarised in the Supporting Informa-
tion. In addition, functional connections showing a difference com-
pared with the resting state network are shown in Figure S7.
Cluster analysis revealed a number of groupings in which similar
pharmacologies co-located (Figure 5), most notably containing close
groupings of monoaminergics (groups 3 and 8 in Figure 5) and cho-
linergics (both mAChR agonists and AChE inhibitors, groups 4 and
5). The majority of drugs that inhibit dopamine (DAT) norepineph-
rine (NET) and 5-HT (serotonin; SERT) transporters located in group
WINTER ET AL. 9
F IGURE 3 Summary of peak fluorescence intensity and functional connectivity data from vehicle (water) control larvae tested across 65
experimental datasets. Panel (a) shows the peak fluorescence intensity data per brain region of interest (ROI) as the average baseline-corrected
fluorescence intensity (Δf/f = (f1 − f0)/f0 * 100, where f1 = peak fluorescence intensity and f0 = baseline fluorescence intensity within each ROI)
of larvae within each control group (per column), presented as the % of the maximum peak intensity shown within that experimental dataset
(n = 7–9 larvae per group). The most active brain region in each dataset is represented by 100%, with decreasing red/orange colour intensity
representing ROIs with lower levels of comparative activity. Note the high consistency across experiments in brain regions exhibiting elevated
basal activity, especially those that showed a mean peak intensity of >33% higher basal activity than the overall mean across all regions:
intermediate hypothalamus, area postrema, inferior olive, locus coeruleus, Mauthner cells, medial vestibular nucleus, inferior raphe, spinal cord
and spinal cord neuropil. Panel (b) shows the resting state functional connectome of control larvae presented as the average across
65 experimental datasets along with a table summarising the 10 most connected brain regions and the 10 strongest functional connections
(n = 516 larvae). Abbreviated brain regions are as follows: area postrema (AP); cerebellum (C); corpus cerebelli (CC); dorsal thalamus (DT); eyes (E);
eminentia granularis (EG); eminentia thalami (ET); habenulae (H); intermediate hypothalamus (I); inferior olive (IO); interpeduncular nucleus (IPN);
lobus caudalis cerebelli (LC); locus coeruleus (Lco); lateral reticular nucleus (LRN); Mauthner (Mt); medial vestibular nucleus (MVN); noradrenergic
neurons of the interfascicular and vagal areas (NIV); spinal cord neuropil (Np); olfactory bulb (OB); olfactory epithelium (OE); pineal (P); preoptic
area (PA); pallium (pa); pretectum (PT); raphe inferior (RI); rostral hypothalamus (Ro); raphe superior (RS); spinal cord (SC); subpallium (Sp);
posterior tuberculum (TB); torus longitudinaris (TL); tegmentum (tm); tectum neurophil (TN); torus semicircularis (TSC); tectum stratum
periventriculare (TSP); tangential vestibular nucleus (TVN); Valvula cerebelli (V); vagal ganglia (VG); ventral thalamus (VT). Note: Positions of
regions approximate to allow spacing of nodes and visualisation of connections
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3, along with phencyclidine and two μ receptor agonists (fentanyl
and meperidine). In contrast with all other antidepressants, amitrip-
tyline exhibited a reduced activity across almost all brain regions
versus the control state (Figure 4), despite widespread modulation
of regional functional interconnectivity (Figures S6 and S7, panel
33). The grouping of several muscarinic agonists and AChE inhibi-
tors together also indicated a common phenotype amongst some
cholinergics, although other class members located elsewhere
(e.g. PF-06767832 and Donepezil, Figures S6 and S7, panels 16 and
23, respectively).
Notably, the GABAA receptor modulators (Figure S6 and S7,
panels 1–5) failed to show common functional connectivity pheno-
types despite showing very high neuroactivity when other metrics
were assessed. Similarly, neither NMDA nor (RS)-(tetrazol-5-yl)glycine
exhibited any particularly strong functional connections (Figure S6,
panels 8 and 9) despite being highly active, perhaps due to
the absence of signal oscillation resulting in a flat waveform (see
Video S1).
3.4 | Alterations in brain region functional
connectivity after exposure to cholinergic and
monoaminergic compounds
Figure 5b shows the number of functional connections for each brain
region that differed after compound treatment, compared with the
same connection in the resting state network. Furthermore, the blue
and red colours, respectively, indicate whether the majority of those
connections exhibited an increase or decrease in the r value compared
with the resting state network and thus whether these connections
were strengthened or weakened by compound treatment. The cholin-
ergics generally showed a reduction in the strength of connectivity
F IGURE 4 Summary of peak GCaMP6s
fluorescence intensity data measured in brain
regions of larvae exposed to a range of
neuroactive test compounds. Column 1 (left)
shows the primary pharmacological mechanism of
action; column 2, the abbreviated compound
name; column 3, the strength of association with
seizure induction in mammals according to the
categories in Figure 2. Data (column 4 onwards)
are expressed as % increase over the same
regions of interest (ROI) from the corresponding
water control group (ΔfT/fC = (f1 − f0)/f0 * 100,
where f1 = treated group and f0 = control group,
mean fluorescence peak height) (n = 6–10 larvae
per group). Colour coding signifies the magnitude
of effect with increasing red colour intensity
signifying an increase, white no change and blue a
decrease compared to the control. Within each
box, statistically significant differences between
compound-treated and control groups are shown
(p < .017): + signifying a significant increase at
one concentration, ++ at two and +++ at three. -,
-- and --- signifies a significant decrease for the
same categories. O signifies an overall difference
only, following Kruskal–Wallis analysis.
Abbreviations are as follows:
GABA = γ-aminobutyric acid; GLU = glutamate;
ACh = acetylcholine; P1/PDE = adenosine/
phosphodiesterase; NA/DA/5-
HT = noradrenaline/dopamine/5-
hydroxytryptamine (serotonin); Kv = potassium
channels; OR = opioid receptor;
αR = α-adrenoreceptor; H = histamine;
CYP = cytochrome P450)
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across most brain regions, with the most commonly connected
regions being the tectum stratum periventriculare, the locus
coeruleus, medial vestibular nucleus and the inferior raphé. Donepezil,
in stark contrast showed a widespread and large increase in functional
connectivity across virtually all brain regions, whilst muscarine and
PF-06767832 showed no effect. The main grouping of
F IGURE 5 Results of the hierarchical cluster and post-hoc analysis of the functional connectivity data. Panel (a) shows the dendrogram
resulting from the cluster analysis on the Euclidean distances between mean r values for each of the compounds assessed. Identified groupings
showing a mean Euclidean distance of no more than 3 (represented by the red dotted line in the dendrogram) are shown in the right hand table
denoted by borders, along with the corresponding primary pharmacological mechanism of action and seizure liability category (as defined in
Figure 2). Grey boxes represent the closest sub groupings. Numbers in the right hand column are references for each defined grouping that
occurs in the corresponding dendrogram. Note in particular, the grouping of specific compounds that share a primary mechanism of action
(e.g., especially groups 3, 4 and 5). Panel (b) shows the results of the post hoc assessment of changes in functional connectivity of each brain
region in compound-treated animals, versus the same region in the resting state network. Abbreviated compound names, along with the primary
pharmacological mechanism of action, seizure liability category and dendrogram group number are shown along the top of the table, with each
registered brain region shown down the left hand side of the table. Each cell shows the number of connections to that region for which the mean
r value had significantly changed versus the equivalent connection in the resting state network. Those boxes coloured red showed a majority of
increased r values, blue a majority of decreases and orange an equal number of increases and decreases (see Figures S6 and S7 for all compound
connectomes). These data reveal the brain regions in which functional connectivity was most significantly changed after compound treatment.
Comparisons were undertaken using Mann–Whitney U tests with a Bonferroni correction applied (significance at p < .00006). A blank cell
signifies there was no change in functional connectivity with any other region when compared to the resting state network. n = 12–19 larvae per
drug exposed group and n = 516 for the resting state network
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monoaminergic drugs (group 3) generally exhibited increased r values
compared with the resting state network suggesting an increase in the
strength of functional connections after compound treatment.
Amongst these, the most consistently connected regions were in the
hindbrain, except for the tegmentum and the intermediate hypothala-
mus which were also prominently connected within the close pairing
of amoxipine and nomifensine (group 8). Amitriptyline was unusual
amongst the monoaminergic reuptake inhibitors in that there was
widespread reduction in functional connections particularly from pos-
terior hind brain regions, although many of the most interconnected
regions were in common with other mood enhancing drugs.
3.5 | Differences in patterns of brain functional
connectivity between most nonseizurogenic and pro-
seizurogenic compounds
Many of the more active seizurogenic compounds exhibited an
increase in the average number of connections and/or in the average
r value per connection compared with the resting state network
(Figure 6), suggesting a tendency towards excitatory synchronisation
between brain regions. Moreover, the weaker acting pro-seizurogenic
and 7/8 nonseizurogenic compounds showed no altered network
activity with respect to either metric used. Assessment of macroscale
functional connectivity (Figure S8) also suggested that seizurogenic
compounds were more likely to exhibit changes in mesencephalic and,
to a lesser degree, diencephalic, functional connectivity compared
with nonseizure-associated compounds. Interestingly, however, the
well-known seizurogenic compounds pilocarpine and bicuculline
showed reductions in the average number and strength of functional
connections.
4 | DISCUSSION
Analysis of the resting state network suggested stimulation from the
imaging environment, with elevated activity apparent in regions
involved in motor coordination and control (Heap et al., 2013), sen-
sory processing (Yokogawa et al., 2012) and physiological homeosta-
sis. Collectively, this mirrors other studies reporting activation of
sensory-motor networks in conscious, immobilised larval zebrafish fol-
lowing external stimulation and subsequent functional imaging
(Ahrens et al., 2012; Migault et al., 2018).
Analysis of GCaMP-indicated brain activity suggested that 4dpf
zebrafish larvae are responsive to a wide range of pharmacologies
associated with the induction of neural network hyperexcitation in
mammals. The mechanistic classes that showed the most consistent
induction of neural activity were the NMDA receptors and GABAA
receptor agonists, glycine receptor agonist, AChE inhibitors and
NA/5-HT/DA reuptake inhibitors. Although not a definitive measure
of brain exposure in 4dpf larvae, the data for whole body compound
uptake in 7dpf larvae provided an indication of where low compound
uptake may be the reason for a relative lack of biological
responsiveness (e.g. in the case of DMCM, domoic acid, Cis-ACPD,
TEA, bethanechol, theobromine and paraxanthine). This highlights the
importance of having some information on relative compound pene-
tration for the interpretation of zebrafish chemical screens and for
identifying false negatives that may occur as the consequence of low
compound uptake (Berghmans et al., 2008; Cassar et al., 2020).
Another important observation is the frequency with which the cere-
bellum and related regions exhibited elevated neural activity after
treatment with seizurogenic compounds. These changes in cerebellar
subregions are likely reflective of activity in the region as a whole as
full differentiation of cerebellar cellular layers is not thought to be
complete until around 6dpf (Volkmann et al., 2008). Nevertheless, the
frequent activation of these regions after exposure to seizurogenic
compounds supports a role for cerebellar circuitry in neural network
hyperexcitation. Previous work in mammals has suggested the cere-
bellum may play an important role in seizures and epilepsy (Rijkers
et al., 2015), and this structure is a recognised target for deep brain
stimulation to treat refractory epilepsy (Fisher, 2013). Furthermore,
activation of the cerebellum has been reported in previous studies of
PTZ-induced seizures in zebrafish (Baraban et al., 2005) and of the
five large brain regions examined by Diaz Verdugo et al. (2019), the
optic tectum and cerebellum appeared influential in the progression
from preictal to ictal states. Liu and Baraban (2019) also observed
propagation of PTZ-induced seizures from the pallium, via the cere-
bellum, to the hind brain perhaps further suggesting that the cerebel-
lum, along with other regions (Diaz Verdugo et al., 2019), may
constitute a key facilitator for the transition from focal to generalised
hypersynchronous excitation.
The absence of any changes in brain activity after exposure to
several other seizurogenic compounds that showed evidence of
uptake suggests that pharmacological insensitivity could be a factor.
Within-class individual compound-insensitivity could be due to subtle
interspecies differences in receptor subtype homology, differences in
the level of local tissue distribution, or temporal methodological insen-
sitivity. For example, the larval zebrafish δ receptor has previously
been shown to have a low affinity for SNC80 (Sanchez-Simon
et al., 2012), PF6767832 is selective for the M1 receptor alone and
larval zebrafish have previously been shown to be insensitive to
cocaine perhaps due to differential tissue partitioning resulting in
reduced central stimulatory activity (Kirla et al., 2016). 4-AP, a well-
known seizurogenic compound, has previously been shown to induce
generalised CNS hyperexcitation, but without consistent induction of
seizures (Liu & Baraban, 2019). Moreover, Liu and Baraban (2019)
reported that fast spiking was detected using electrophysiological, but
not Ca2+ imaging approaches and that 4-AP exposure results in dis-
persed small activated neuronal clusters. This perhaps suggests that
the mesoscale segmentation and temporal resolution of our system is
not sufficient for the consistent capture of fast ictal events induced
by 4-AP and certain other compounds; therefore, faster, higher reso-
lution systems may be needed for full neuropharmacological func-
tional imaging coverage. In contrast, exposure to the centrally acting
α2-adrenoceptor agonist clonidine resulted in a surprisingly high
degree of CNS activation. Analysis of 7dpf larval locomotor activity,
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however, revealed a biphasic response comparable to that following
Ca2+ imaging and such a dose–response relationship has been
reported previously in relation to anxiolysis versus anxiogenesis in rats
(Söderpalm & Engel, 1988). Furthermore, although clonidine is a puta-
tive anticonvulsant, there are very limited data suggesting seizure
induction under specific circumstances (Feron et al., 2008). Quinine
F IGURE 6 Assessment of average functional connectivity across the whole brain. Panel (a) shows a comparison of the functional connectivity
across the whole brain of larvae exposed to each compound compared with the resting state network animals. Data are shown as the %
difference in the number of functional connections between the two groups (where r > .7) along with the corresponding p value generated after
Mann–Whitney U testing, along with the same parameters for the average r value of the two groups. Compounds are listed in order of the % size
difference from the highest to lowest with values highlighted in red signifying increases and those in a blue decreases compared with the control
value. p values highlighted in pale yellow were statistically significant (p < .05). Note that most compounds with no known association to seizure
showed no change in functional connectivity versus the resting state network, whereas the stronger seizurogenic compounds (especially the
precipitants) generally showed an increase in functional connectivity. Note also that some known seizurogenic compounds also exhibited a
decrease in functional connectivity compared with the resting state network. Panel (b) shows representative connectomes from compounds
across the full range of values from those showing a large increase in functional connectivity (top), to those showing a large decrease in functional
connectivity (bottom). Data shown are connections that exhibited a different mean r value compared with the equivalent connection as a mean of
all the vehicle (water) control animals tested. Nodes connected with a red line represent significant increases and blue significant decreases in the
r value compared with the control. Nodes labelled in green showed 1 or more significantly different connections, in blue, 5 or more and in red
10 or more. Comparisons here were undertaken using Mann–Whitney U tests with a Bonferroni correction applied (significance at p < .00006).
n = 12–19 larvae per drug exposed group and n = 516 for the resting state network. Abbreviated brain regions as detailed in Figure 3. Note:
Positions of regions approximate to allow spacing of nodes and optimal visualisation of connectivity
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exposure also resulted in elevated CNS activity in a small number of
brain regions perhaps due to its known blockade of several K+ chan-
nels (Zou et al., 2018). The most strongly activated region was the
medial vestibular nucleus, which is of particular interest given the
known potent inhibitory effect of quinine on mechanosensory hair
cells of the lateral line (Thomas et al., 2013) and may point to compen-
satory activation linked to vestibular inhibition in these animals.
Most of the D-classified compounds showed relatively low levels
of CNS activation or suppression with the exception of nomifensine,
galantamine and caffeine. Nomifensine is a NA/DA reuptake inhibitor
which has been linked with seizures in the clinic (Edwards &
Glen-Bott, 1987) and is known to increase locomotion in mice
(Kitanaka et al., 2012) supporting the potential for neural-excitation.
Similarly, caffeine predominantly exerts its CNS stimulatory effects
through adenosine receptor antagonism and has a well-established
association with seizures but only at high dose levels (van Koert
et al., 2018).
Amitriptyline and carbachol rather unexpectedly exhibited
decreases in activity across multiple brain regions. Of these, amitripty-
line also showed an inhibitory effect on larval locomotion and very
high compound uptake. A sedative-like effect has previously been
seen in adult zebrafish exposed to amitriptyline (Demin et al., 2017)
and its known sedative effects in mammals are likely driven by activity
at the histamine H1 receptor (Lawson, 2017). Similarly, carbachol is
also known to be a sedative in rats, an effect likely driven by action on
the M2 receptors of the brainstem (Ma et al., 2001).
To date, functional connectivity analysis of zebrafish neural activ-
ity has been limited to few studies. Rosch et al. (2018) for example
used dynamic causal modelling to reveal the optic tectum may be cen-
tral in driving network wide synchronisation and Diaz Verdugo
et al. (2019) used pairwise correlation analysis (as used here) to show
that glia may play an important role in the transition to a seizure. Our
assessment of functional connectivity served two purposes:- first, we
hypothesised that functional connectivity phenotypes would reflect
mechanism-specific circuit activation or inhibition in 4dpf larvae and
thus reveal differences between mechanisms of action, and second,
that changes in overall functional connectivity would support a trend
for the mesoscale and macroscale hypersynchronisation characteristic
of seizure induction after activation via a range of pharmacological
mechanisms of action. Our functional connectivity data revealed that
larvae exposed to certain cholinergics and monoaminergic reuptake
inhibitors showed common features within their phenotypes. Notably,
both muscarinic agonists and AChE inhibitors grouped together
suggesting a common cholinergic phenotype. The most prominent
regions showing altered connectivity after exposure to cholinergics
were the tectum stratum periventriculare, locus coeruleus, medial ves-
tibular nucleus and the inferior raphe. The development of the cholin-
ergic system in the zebrafish CNS was described by Arenzana
et al. (2005), who reported that spatiotemporal development from
2dpf to 5dpf followed a caudorostral gradient. Our data also support
preferentially altered functional connectivity in hind brain regions
after treatment with cholinergic agents but of course reflect wider
synaptic connectivity, as exemplified by the widespread activity of
donepezil, rather than discrete distributions of cell bodies or subcellu-
lar receptor populations. Also of note was the close grouping of the
Kv blocker XE991 and pilocarpine. Importantly, XE991 is Kv7-
selective and inhibition of Kv7 is known to be excitatory, functionally
mimicking the direct agonism of muscarinic receptors, which in turn
initiates channel closure and aspects of cholinergic stimulation
(Brown, 2018).
The other class of compounds showing notable similarities
amongst their functional connectivity phenotypes were the monoam-
inergic reuptake inhibitors. There was also subdivision of these com-
pounds that may be reflective of the subtle balance in efficacy against
each (zebrafish) transporter (Huot et al., 2015) and further work with
more selective modulators would help to clarify this. Analysis of the
brain regions showing the greatest changes in functional connectivity
supported effects on noradrenaline and 5-HT circuitry. Aminergic
neurons are also amongst the first to develop in zebrafish. Noradren-
ergic pathways mainly originate from the locus coeruleus; dopaminer-
gic projections from the posterior tuberculum (Tay et al., 2011) and
5-HT neurons from the raphé nuclei (Maximino & Herculano, 2010).
Linking these regions is the important relay station, the inter-
peduncular nucleus (Bianco & Wilson, 2009), which was also
prominently connected here. Altered functional connectivity with the
tegmentum is also notably associated with compounds showing
relative dopaminergic activity (e.g. cocaine, amphetamine and
nomifensine). Given that the tegmentum is known to be relatively rich
in zebrafish D2A receptors (Maximino & Herculano, 2010), this may
suggest that dopaminergic activity is influencing these phenotypes in
contrast with other groupings where the more subtle balance
between NET and SERT activity is the predominant driving force. The
co-location of fentanyl, meperidine and phencyclidine with several
monoaminergic reuptake inhibitors could be explained by interactions
between these neurotransmitter systems, for example, the reported
inhibition of the human SERT and NET by meperidine at low μM con-
centrations (Rickli et al., 2018) and the inhibition of NA and DA reup-
take at low μM concentrations in rat hippocampus (Snell et al., 1988).
Using our analysis method, some pharmacological classes showed
few similarities in their functional imaging phenotypes despite being
extremely neuroactive in 4dpf larvae. Amongst the GABAA modula-
tors tested, for example, this dissimilarity may be driven by differ-
ences in receptor subtype distribution and relative ligand efficacy
(Bandara et al., 2020; Johnston, 2013). Alternatively, this may be
reflective of the broad distribution of GABAA receptors across the
CNS, meaning that targets with a more punctate spatial distribution,
such as with the monoaminergics, are more easily differentiated using
functional connectivity analysis. Similarly, despite being neuroactive
neither NMDA nor (RS)-(tetrazol-5-yl)glycine exhibited any particu-
larly strong functional connections. This could be the result of
agonism-induced global depolarization resulting in blockade of synap-
tic transmission in which the Ca2+ rise (and associated GCamp fluores-
cence) would remain due to Ca2+ entry via the NMDAR itself and
depolarization-mediated gating of voltage-gated Ca2+ channels.
Extending previous findings using PTZ (Diaz Verdugo et al., 2019;
Liu & Baraban, 2019), here we demonstrate altered functional
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connectivity resulting from compound treatment across a wide range
of pharmacological mechanisms of action implicated in seizure genera-
tion, particularly amongst compounds used as precipitants in animal
models of seizure and epilepsy. The presence of abnormal synchroni-
sation is a key feature of seizure networks, as reported in experimen-
tal and clinical assessments of epileptic seizures (Jiruska et al., 2013).
Our data also revealed an increased prevalence of altered functional
connectivity involving nodes within the mesencephalon, in particular,
as well as in the diencephalon after exposure to compounds associ-
ated with seizures. This echoes the results of previous authors using
broader scale segmentation (e.g. Diaz Verdugo et al., 2019; Rosch
et al., 2018), who have suggested large midbrain structures, such as
the optic tectum, play an important role as hubs in the transition of
preictal to ictal network dynamics after exposure to the GABAA
antagonist PTZ. Whole brain connectivity analysis also revealed a
reduced overall functional connectivity after exposure to several com-
pounds, most notably pilocarpine and bicuculline. Cymerblit-Sabba
and Schiller (2012) found that overall network synchronicity
decreased in the initial stages of a seizure after systemically applied
pilocarpine or an intrahippocampal applied mixture of pilocarpine,
kainate and picrotoxin in rats and that hypersynchronisation devel-
oped only as seizures progressed and intensified. It may, therefore, be
the case here that longer term exposure of some compounds is
required in order to reach the advanced stages of a seizure and allow
a hypersynchronous phenotype to emerge.
Concluding, we present data demonstrating the power of func-
tional brain imaging in larval zebrafish for assessing the action of neu-
roactive drugs in a highly relevant vertebrate model. These data help
us to understand the relevance of the 4dpf larval zebrafish for neuro-
pharmacological studies and reveal that even at this early develop-
ment stage, these animals are highly responsive to a wide range of
neuroactive compounds across multiple primary mechanisms of
action. The 4dpf larva appears a particularly relevant model for the
study of drugs affecting the monoaminergic and cholinergic systems
and has potential utility for the assessment of new drugs targeting
these circuits. Furthermore, the assessment of neural activity levels
and overall network functional connectivity could help to identify
unwanted seizure liability in drugs as part of a new drug CNS safety
assessment cascade, as well as aiding in the identification and charac-
terisation of new anti-epileptic drugs and therapeutic targets
(Ghannad-Rezaie et al., 2019). This approach also has high potential as
an in vivo model for the study of seizurogenic and epileptogenic
mechanisms more widely, especially with advances in spatiotemporal
resolution driving a move towards real time-imaging of large-scale
neuronal assemblies at cellular, or even subcellular, resolutions.
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